NEW ALZHEIMER'S DISEASE PAGE
Review of the rapidly evolving treatment and diagnosis of Alzheimer's disease
Straight Healthcare
November 2026
November 2026
As people live longer, Alzheimer's disease is becoming a larger part of everyday clinical practice. Roughly 7.2 million Americans aged 65 years and older are living with Alzheimer's dementia in 2025, and prevalence rises sharply with age. Without major advances in prevention or disease modification, that number could approach 14 million by 2060. Patients and families increasingly bring questions about memory loss, testing, and newly advertised therapies to primary care visits, and providers should be prepared to offer advice.
Alzheimer's diagnosis and treatment have evolved rapidly over the past 3 to 5 years. Blood-based biomarkers are increasingly used for diagnostic testing, and anti-amyloid monoclonal antibodies—lecanemab (Leqembi®) and donanemab (Kisunla®)—are now approved to treat early symptomatic disease. These anti-amyloid therapies have shown modest effects in trials and have significant side effects, including brain bleeds in up to 25% of patients, that must be monitored.
Our new Alzheimer's disease page condenses evolving information into a primary care-friendly format: epidemiology, risk factors, pathology, symptoms, Alzheimer's Association (AA) classification, a practical diagnostic pathway (including cognitive tools, imaging, CSF, blood tests, and differential diagnosis), treatment and appropriate-use points for anti-amyloid therapy, full monographs for lecanemab, donanemab, donepezil, and memantine, and a review of pivotal trials. Most primary care physicians will not manage anti-amyloid infusions; however, they should still be able to answer common patient questions about new therapies, explain what blood and imaging tests mean at a high level, and know when specialist evaluation is appropriate.
Alzheimer's diagnosis and treatment have evolved rapidly over the past 3 to 5 years. Blood-based biomarkers are increasingly used for diagnostic testing, and anti-amyloid monoclonal antibodies—lecanemab (Leqembi®) and donanemab (Kisunla®)—are now approved to treat early symptomatic disease. These anti-amyloid therapies have shown modest effects in trials and have significant side effects, including brain bleeds in up to 25% of patients, that must be monitored.
Our new Alzheimer's disease page condenses evolving information into a primary care-friendly format: epidemiology, risk factors, pathology, symptoms, Alzheimer's Association (AA) classification, a practical diagnostic pathway (including cognitive tools, imaging, CSF, blood tests, and differential diagnosis), treatment and appropriate-use points for anti-amyloid therapy, full monographs for lecanemab, donanemab, donepezil, and memantine, and a review of pivotal trials. Most primary care physicians will not manage anti-amyloid infusions; however, they should still be able to answer common patient questions about new therapies, explain what blood and imaging tests mean at a high level, and know when specialist evaluation is appropriate.
